Drug
Palbociclib clinical trials
Also written Ibrance, PD-0332991 and PD 332991.
- studies test it
- 236
- open now
- 41
- in phase 3
- 22
- first study started
- 2004
Keep track of what changes. Save the palbociclib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
236 studies that test it; most in 2017 (31)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 8 |
| 2014 | 17 |
| 2015 | 24 |
| 2016 | 19 |
| 2017 | 31 |
| 2018 | 27 |
| 2019 | 18 |
| 2020 | 13 |
| 2021 | 17 |
| 2022 | 13 |
| 2023 | 8 |
| 2024 | 13 |
| 2025 | 9 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 4
- Phase 1
- 87
- Phase 2
- 136
- Phase 3
- 22
- Phase 4
- 7
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 59 · Other 177
Pfizer (27) · National Cancer Institute (NCI) (9) · Dana-Farber Cancer Institute (9) · Washington University School of Medicine (5) · Memorial Sloan Kettering Cancer Center (5) · Abramson Cancer Center at Penn Medicine (4) · Hoffmann-La Roche (4) · AstraZeneca (4)
Often tested with
Tested in the same studies.
Fulvestrant (30) · Letrozole (23) · Abemaciclib (14) · Olaparib (14) · Trastuzumab (13) · Ribociclib (13) · Paclitaxel (10) · Everolimus (10)
Studies
Open first, then newest update. How each study uses palbociclib is read from its arms, and is right about nine times in ten.
Testing it · 236
- A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesRecruitingPhase 2Hoffmann-La RocheNCT07748208Written as Palbociclib
- Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06126276Written as Palbociclib
- T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingPhase 3Daiichi SankyoNCT07683754Written as Palbociclib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Palbociclib
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingPhase 3Celcuity IncNCT06757634Written as Arm A: Gedatolisib + Palbociclib + Fulvestrant
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Palbociclib
- The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyRecruitingPhase 3American Society of Clinical OncologyNCT06377852Written as Palbociclib 125mg
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Written as Palbociclib
- Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 InhibitorRecruitingPhase 3Washington University School of MedicineNCT04966481Written as Palbociclib
- A Study of Mirdametinib in Combination With Palbociclib in People With LiposarcomaRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06843967Written as Palbociclib
- Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingPhase 2Northwestern UniversityNCT06062498Written as elacestrant, palbociclib, abemaciclib, ribociclib
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751Written as Palbociclib
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell CarcinomaRecruitingPhase 2Stephanie BergNCT07123090Written as Palbociclib
- Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid TumorsRecruitingPhase 1UNC Lineberger Comprehensive Cancer CenterNCT03454035Written as Palbociclib
- Palbociclib and Pembrolizumab in SarcomaRecruitingPhase 1John RiethNCT06113809Written as Palbociclib
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as Palbociclib
- Tazemetostat and Palbociclib With CPX-351for R/R AMLRecruitingPhase 1Thomas Jefferson UniversityNCT05627232Written as Palbociclib
- Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingPhase 2West China HospitalNCT07191977Written as Palbociclib
- Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast CancerNot yet recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07061717Written as Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd
- A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS MutationsRecruitingPhase 1/2Sun Yat-sen UniversityNCT06947811Written as Palbociclib
See all 236 studies that test palbociclib →
Given in every arm · 56 — palbociclib is usual care beside what is tested
- Study of PF-07248144 in Advanced or Metastatic Solid TumorsRecruitingPhase 2PfizerNCT04606446Written as Palbociclib
- Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)RecruitingPhase 1/2National Cancer Institute (NCI)NCT05665361Written as Palbocicilib
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingPhase 3Eli Lilly and CompanyNCT07174336Written as Palbociclib
- A Phase 1/2a Study of K-1728 in Advanced Solid TumorsNot yet recruitingPhase 1/2KymaThera, Inc.NCT07861932Written as Palbociclib
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsRecruitingPhase 1Bristol-Myers SquibbNCT06997029Written as Palbociclib
- Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingPhase 1/2Avenzo Therapeutics, Inc.NCT05867251Written as Palbociclib
- A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid TumorsNot yet recruitingPhase 1Laekna LimitedNCT07787520Written as Palbociclib
- Palbociclib and Pembrolizumab In Central Nervous System MetastasesRecruitingPhase 2Massachusetts General HospitalNCT02896335Written as Palbociclib
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingPhase 1/2Eli Lilly and CompanyNCT05768139Written as Palbociclib
- A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast CancerRecruitingPhase 1Totus MedicinesNCT05683418Written as Palbociclib
- SNV4818 in Participants With Advanced Solid TumorsRecruitingPhase 1/2Pikavation Therapeutics, Inc.NCT06736704Written as Palbociclib
- A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BCRecruitingPhase 1/2Forward Pharmaceuticals Co., Ltd.NCT07002177Written as Palbociclib 125mg
- Combined Immunotherapies in Metastatic ER+ Breast CancerRecruitingPhase 2Weill Medical College of Cornell UniversityNCT04563507Written as Palbociclib 125mg
- A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 1/2West China HospitalNCT06753747Written as Palbociclib
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerRecruitingPhase 1Relay Therapeutics, Inc.NCT05216432Written as Palbociclib 125mg
- Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNARecruitingPhase 1Lebanese UniversityNCT06307249Written as Palbociclib 125mg
- A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1/2AstraZenecaNCT06188520Written as Palbociclib
- Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated LiposarcomaActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT05694871Written as Palbociclib
- Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory LeukemiaActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT03132454Written as Palbociclib
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseActive, not recruitingPhase 3AstraZenecaNCT04711252Written as Palbociclib
Showing 20 of 56.
As the comparator · 2 — what is tested is compared with palbociclib
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseRecruitingPhase 3BeOne MedicinesNCT07492641Written as Palbociclib
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseActive, not recruitingPhase 3PfizerNCT06760637Written as palbociclib
Codes
What other systems call palbociclib · ClinicalTrials.gg INT004770
- MeSH (NLM) C500026palbociclibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) G9ZF61LE7GPALBOCICLIBConfirmed FDA, NLM, Wikidata
- RxNorm 1601374Confirmed FDA, Wikidata
- Wikidata Q15269707palbociclibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C49176PalbociclibOne source FDA
- DrugBank DB09073One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C500026 | palbociclib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | G9ZF61LE7G | PALBOCICLIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1601374 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15269707 | palbociclib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C49176 | Palbociclib | One source FDA |
| DrugBank | DB09073 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.